{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T02:51:35Z","timestamp":1793674295372,"version":"4.5.1"},"reference-count":38,"publisher":"Journal of Neurosurgery Publishing Group (JNSPG)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,10]]},"abstract":"\n OBJECTIVE<\/jats:title>\n Delivery of drugs intraarterially to brain tumors has been demonstrated in adults. In this study, the authors initiated a phase I trial of superselective intraarterial cerebral infusion (SIACI) of bevacizumab and cetuximab in pediatric patients with refractory high-grade glioma (diffuse intrinsic pontine glioma [DIPG] and glioblastoma) to determine the safety and efficacy in this population.<\/jats:p>\n <\/jats:sec>\n \n METHODS<\/jats:title>\n \n SIACI was used to deliver mannitol (12.5 ml of 20% mannitol) to disrupt the blood-brain barrier (BBB), followed by bevacizumab (15 mg\/kg) and cetuximab (200 mg\/m\n 2<\/jats:sup>\n ) to target VEGF and EGFR, respectively. Patients with brainstem tumors had a balloon inflated in the distal basilar artery during mannitol infusion.\n <\/jats:p>\n <\/jats:sec>\n \n RESULTS<\/jats:title>\n Thirteen patients were treated (10 with DIPG and 3 with high-grade glioma). Toxicities included grade I epistaxis (2 patients) and grade I rash (2 patients). There were no dose-limiting toxicities. Of the 10 symptomatic patients, 6 exhibited subjective improvement; 92% showed decreased enhancement on day 1 posttreatment MRI. Of 10 patients who underwent MRI at 1 month, 5 had progressive disease and 5 had stable disease on FLAIR, whereas contrast-enhanced scans demonstrated progressive disease in 4 patients, stable disease in 2, partial response in 2, and complete response in 1. The mean overall survival for the 10 DIPG patients was 519 days (17.3 months), with a mean posttreatment survival of 214.8 days (7.2 months).<\/jats:p>\n <\/jats:sec>\n \n CONCLUSIONS<\/jats:title>\n SIACI of bevacizumab and cetuximab was well tolerated in all 13 children. The authors\u2019 results demonstrate safety of this method and warrant further study to determine efficacy. As molecular targets are clarified, novel means of bypassing the BBB, such as intraarterial therapy and convection-enhanced delivery, become more critical.<\/jats:p>\n \n Clinical trial registration no.: NCT01884740 (\n clinicaltrials.gov<\/jats:ext-link>\n )\n <\/jats:p>\n <\/jats:sec>","DOI":"10.3171\/2021.3.peds20738","type":"journal-article","created":{"date-parts":[[2021,8,6]],"date-time":"2021-08-06T03:11:43Z","timestamp":1628219503000},"page":"371-379","source":"Crossref","is-referenced-by-count":58,"title":["Intraarterial delivery of bevacizumab and cetuximab utilizing blood-brain barrier disruption in children with high-grade glioma and diffuse intrinsic pontine glioma: results of a phase I trial"],"prefix":"10.3171","volume":"28","author":[{"given":"Heather J.","family":"McCrea","sequence":"first","affiliation":[{"name":"Department of Neurological Surgery, University of Miami Miller School of Medicine, Miami, Florida;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jana","family":"Ivanidze","sequence":"additional","affiliation":[{"name":"Department of Radiology, NewYork-Presbyterian Hospital\u2014Weill Cornell Medicine, New York, New York;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashley","family":"O\u2019Connor","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, NewYork-Presbyterian Hospital\u2014Weill Cornell Medicine, New York, New York; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eliza H.","family":"Hersh","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, NewYork-Presbyterian Hospital\u2014Weill Cornell Medicine, New York, New York; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John A.","family":"Boockvar","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Lenox Hill Hospital\/Hofstra Northwell School of Medicine, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y. Pierre","family":"Gobin","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, NewYork-Presbyterian Hospital\u2014Weill Cornell Medicine, New York, New York; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jared","family":"Knopman","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, NewYork-Presbyterian Hospital\u2014Weill Cornell Medicine, New York, New York; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey P.","family":"Greenfield","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, NewYork-Presbyterian Hospital\u2014Weill Cornell Medicine, New York, New York; and"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1754","reference":[{"key":"b1","series-title":"NCHS Data Brief","first-page":"1","article-title":"Declines in cancer death rates among children and adolescents in the United States, 1999-2014","volume":"257","author":"Curtin SC","year":"2016","unstructured":"Curtin SC, Minino AM, Anderson RN. Declines in cancer death rates among children and adolescents in the United States, 1999-2014. NCHS Data Brief. 2016;(257):1\u20138."},{"issue":"suppl 4","key":"b2","series-title":"Neuro Oncol","doi-asserted-by":"publisher","first-page":"iv1","DOI":"10.1093\/neuonc\/nov189","article-title":"CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2008-2012","volume":"17","author":"Ostrom QT","year":"2015","unstructured":"Ostrom QT, Gittleman H, Fulop J, CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2008-2012. Neuro Oncol. 2015;17(suppl 4):iv1\u2013iv62.10.1093\/neuonc\/nov18926511214"},{"issue":"3","key":"b3","series-title":"Lancet Oncol","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/S1470-2045(06)70615-5","article-title":"Diffuse brainstem glioma in children: critical review of clinical trials","volume":"7","author":"Hargrave D","year":"2006","unstructured":"Hargrave D, Bartels U, Bouffet E. Diffuse brainstem glioma in children: critical review of clinical trials. Lancet Oncol. 2006;7(3):241\u2013248.10.1016\/S1470-2045(06)70615-516510333"},{"issue":"6","key":"b4","series-title":"Arch Dis Child","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1136\/adc.80.6.558","article-title":"Clinical management of brain stem glioma","volume":"80","author":"Walker DA","year":"1999","unstructured":"Walker DA, Punt JA, Sokal M. Clinical management of brain stem glioma. Arch Dis Child. 1999;80(6):558\u2013564.10.1136\/adc.80.6.55810332008"},{"issue":"3","key":"b5","series-title":"Childs Nerv Syst","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1007\/s00381-003-0870-6","article-title":"Brainstem gliomas","volume":"20","author":"Jallo GI","year":"2004","unstructured":"Jallo GI, Biser-Rohrbaugh A, Freed D. Brainstem gliomas. Childs Nerv Syst. 2004;20(3):143\u2013153.1466902310.1007\/s00381-003-0870-6"},{"issue":"suppl 5","key":"b6","series-title":"Neuro Oncol","doi-asserted-by":"publisher","first-page":"v1","DOI":"10.1093\/neuonc\/nos218","article-title":"CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2005-2009","volume":"14","author":"Dolecek TA","year":"2012","unstructured":"Dolecek TA, Propp JM, Stroup NE, Kruchko C. CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2005-2009. Neuro Oncol. 2012;14(suppl 5):v1\u2013v49.2309588110.1093\/neuonc\/nos218"},{"issue":"9","key":"b7","series-title":"Childs Nerv Syst","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1007\/s00381-006-0083-x","article-title":"Diffuse and focal brain stem tumors in childhood: prognostic factors and surgical outcome. Experience in a single institution","volume":"22","author":"Sandri A","year":"2006","unstructured":"Sandri A, Sardi N, Genitori L, Diffuse and focal brain stem tumors in childhood: prognostic factors and surgical outcome. Experience in a single institution. Childs Nerv Syst. 2006;22(9):1127\u20131135.10.1007\/s00381-006-0083-x"},{"issue":"4","key":"b8","series-title":"Pediatr Neurosurg","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1159\/000121036","article-title":"Brainstem gliomas in children. A Children\u2019s Cancer Group review of 119 cases","volume":"24","author":"Kaplan AM","year":"1996","unstructured":"Kaplan AM, Albright AL, Zimmerman RA, Brainstem gliomas in children. A Children\u2019s Cancer Group review of 119 cases. Pediatr Neurosurg. 1996;24(4):185\u2013192.10.1159\/0001210368873160"},{"issue":"3","key":"b9","series-title":"Neurosurgery","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1227\/NEU.0000000000000845","article-title":"Sex, age, anatomic location, and extent of resection influence outcomes in children with high-grade glioma","volume":"77","author":"McCrea HJ","year":"2015","unstructured":"McCrea HJ, Bander ED, Venn RA, Sex, age, anatomic location, and extent of resection influence outcomes in children with high-grade glioma. Neurosurgery. 2015;77(3):443\u2013453.10.1227\/NEU.000000000000084526083157"},{"issue":"3","key":"b10","series-title":"J Neurooncol","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1007\/s11060-006-9133-1","article-title":"Treatment options in childhood pontine gliomas","volume":"79","author":"Wagner S","year":"2006","unstructured":"Wagner S, Warmuth-Metz M, Emser A, Treatment options in childhood pontine gliomas. J Neurooncol. 2006;79(3):281\u2013287.10.1007\/s11060-006-9133-116598416"},{"issue":"6","key":"b11","series-title":"Acta Neuropathol","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1007\/s00401-016-1545-1","article-title":"The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary","volume":"131","author":"Louis DN","year":"2016","unstructured":"Louis DN, Perry A, Reifenberger G, The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathol. 2016;131(6):803\u2013820.2715793110.1007\/s00401-016-1545-1"},{"issue":"1","key":"b12","series-title":"J Clin Oncol","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1200\/JCO.1995.13.1.112","article-title":"Randomized phase III trial in childhood high-grade astrocytoma comparing vincristine, lomustine, and prednisone with the eight-drugs-in-1-day regimen","volume":"13","author":"Finlay JL","year":"1995","unstructured":"Finlay JL, Boyett JM, Yates AJ, Randomized phase III trial in childhood high-grade astrocytoma comparing vincristine, lomustine, and prednisone with the eight-drugs-in-1-day regimen. J Clin Oncol. 1995;13(1):112\u2013123.10.1200\/JCO.1995.13.1.1127799011"},{"issue":"1","key":"b13","series-title":"Cancer","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1002\/cncr.10114","article-title":"Preradiation chemotherapy for pediatric patients with high-grade glioma","volume":"94","author":"Wolff JE","year":"2002","unstructured":"Wolff JE, Gnekow AK, Kortmann RD, Preradiation chemotherapy for pediatric patients with high-grade glioma. Cancer. 2002;94(1):264\u2013271.10.1002\/cncr.1011411815986"},{"issue":"2","key":"b14","series-title":"J Neurooncol","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1007\/BF00165101","article-title":"The effectiveness of chemotherapy for treatment of high grade astrocytoma in children: results of a randomized trial. A report from the Childrens Cancer Study Group","volume":"7","author":"Sposto R","year":"1989","unstructured":"Sposto R, Ertel IJ, Jenkin RD, The effectiveness of chemotherapy for treatment of high grade astrocytoma in children: results of a randomized trial. A report from the Childrens Cancer Study Group. J Neurooncol. 1989;7(2):165\u2013177.10.1007\/BF00165101"},{"issue":"3","key":"b15","series-title":"Cancer","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1002\/(SICI)1097-0142(19970801)80:3<497::AID-CNCR18>3.0.CO;2-S","article-title":"Supratentorial malignant gliomas in childhood: a single institution perspective","volume":"80","author":"Heideman RL","year":"1997","unstructured":"Heideman RL, Kuttesch J Jr, Gajjar AJ, Supratentorial malignant gliomas in childhood: a single institution perspective. Cancer. 1997;80(3):497\u2013504.10.1002\/(SICI)1097-0142(19970801)80:3<497::AID-CNCR18>3.0.CO;2-S9241084"},{"issue":"2","key":"b16","series-title":"J Neurooncol","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1007\/s11060-015-1969-9","article-title":"Tumor location, but not H3.3K27M, significantly influences the blood-brain-barrier permeability in a genetic mouse model of pediatric high-grade glioma","volume":"126","author":"Subashi E","year":"2016","unstructured":"Subashi E, Cordero FJ, Halvorson KG, Tumor location, but not H3.3K27M, significantly influences the blood-brain-barrier permeability in a genetic mouse model of pediatric high-grade glioma. J Neurooncol. 2016;126(2):243\u2013251.10.1007\/s11060-015-1969-926511492"},{"issue":"5","key":"b17","series-title":"J Nucl Med","doi-asserted-by":"publisher","first-page":"617","DOI":"10.2967\/jnumed.118.218792","article-title":"A distinct advantage to intraarterial delivery of 89Zr-bevacizumab in PET imaging of mice with and without osmotic opening of the blood-brain barrier","volume":"60","author":"Lesniak WG","year":"2019","unstructured":"Lesniak WG, Chu C, Jablonska A, A distinct advantage to intraarterial delivery of 89Zr-bevacizumab in PET imaging of mice with and without osmotic opening of the blood-brain barrier. J Nucl Med. 2019;60(5):617\u2013622.3031514610.2967\/jnumed.118.218792"},{"issue":"1","key":"b18","series-title":"Nat Commun","doi-asserted-by":"publisher","first-page":"2621","DOI":"10.1038\/s41467-019-10588-0","article-title":"Hypoxia-enhanced Blood-Brain Barrier Chip recapitulates human barrier function and shuttling of drugs and antibodies","volume":"10","author":"Park TE","year":"2019","unstructured":"Park TE, Mustafaoglu N, Herland A, Hypoxia-enhanced Blood-Brain Barrier Chip recapitulates human barrier function and shuttling of drugs and antibodies. Nat Commun. 2019;10(1):2621.10.1038\/s41467-019-10588-031197168"},{"issue":"3","key":"b19","series-title":"J Neurooncol","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1007\/s11060-016-2099-8","article-title":"Superselective intraarterial cerebral infusion of cetuximab after osmotic blood\/brain barrier disruption for recurrent malignant glioma: phase I study","volume":"128","author":"Chakraborty S","year":"2016","unstructured":"Chakraborty S, Filippi CG, Wong T, Superselective intraarterial cerebral infusion of cetuximab after osmotic blood\/brain barrier disruption for recurrent malignant glioma: phase I study. J Neurooncol. 2016;128(3):405\u2013415.10.1007\/s11060-016-2099-826945581"},{"issue":"10","key":"b20","series-title":"Cancer","doi-asserted-by":"publisher","first-page":"2267","DOI":"10.1002\/cncr.23401","article-title":"Treatment with bevacizumab and irinotecan for recurrent high-grade glial tumors","volume":"112","author":"Bokstein F","year":"2008","unstructured":"Bokstein F, Shpigel S, Blumenthal DT. Treatment with bevacizumab and irinotecan for recurrent high-grade glial tumors. Cancer. 2008;112(10):2267\u20132273.10.1002\/cncr.2340118327820"},{"issue":"1","key":"b21","series-title":"J Neurooncol","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1007\/s11060-008-9599-0","article-title":"Irinotecan and bevacizumab in progressive primary brain tumors, an evaluation of efficacy and safety","volume":"89","author":"Kang TY","year":"2008","unstructured":"Kang TY, Jin T, Elinzano H, Peereboom D. Irinotecan and bevacizumab in progressive primary brain tumors, an evaluation of efficacy and safety. J Neurooncol. 2008;89(1):113\u2013118.10.1007\/s11060-008-9599-018438609"},{"issue":"1","key":"b22","series-title":"Neuro Oncol","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1215\/15228517-2008-075","article-title":"Experience with irinotecan for the treatment of malignant glioma","volume":"11","author":"Vredenburgh JJ","year":"2009","unstructured":"Vredenburgh JJ, Desjardins A, Reardon DA, Friedman HS. Experience with irinotecan for the treatment of malignant glioma. Neuro Oncol. 2009;11(1):80\u201391.10.1215\/15228517-2008-07518784279"},{"issue":"2","key":"b23","series-title":"Int J Radiat Oncol Biol Phys","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/j.ijrobp.2008.05.062","article-title":"Feasibility of using bevacizumab with radiation therapy and temozolomide in newly diagnosed high-grade glioma","volume":"72","author":"Narayana A","year":"2008","unstructured":"Narayana A, Golfinos JG, Fischer I, Feasibility of using bevacizumab with radiation therapy and temozolomide in newly diagnosed high-grade glioma. Int J Radiat Oncol Biol Phys. 2008;72(2):383\u2013389.10.1016\/j.ijrobp.2008.05.06218793954"},{"issue":"3","key":"b24","series-title":"J Neurooncol","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1007\/s11060-008-9718-y","article-title":"Efficacy, safety and patterns of response and recurrence in patients with recurrent high-grade gliomas treated with bevacizumab plus irinotecan","volume":"91","author":"Zuniga RM","year":"2009","unstructured":"Zuniga RM, Torcuator R, Jain R, Efficacy, safety and patterns of response and recurrence in patients with recurrent high-grade gliomas treated with bevacizumab plus irinotecan. J Neurooncol. 2009;91(3):329\u2013336.1895349310.1007\/s11060-008-9718-y"},{"issue":"3","key":"b25","series-title":"J Neurosurg","doi-asserted-by":"publisher","first-page":"624","DOI":"10.3171\/2010.9.JNS101223","article-title":"Safety and maximum tolerated dose of superselective intraarterial cerebral infusion of bevacizumab after osmotic blood-brain barrier disruption for recurrent malignant glioma. Clinical article","volume":"114","author":"Boockvar JA","year":"2011","unstructured":"Boockvar JA, Tsiouris AJ, Hofstetter CP, Safety and maximum tolerated dose of superselective intraarterial cerebral infusion of bevacizumab after osmotic blood-brain barrier disruption for recurrent malignant glioma. Clinical article. J Neurosurg. 2011;114(3):624\u2013632.10.3171\/2010.9.JNS10122320964595"},{"issue":"7","key":"b26","series-title":"Nat Rev Clin Oncol","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1038\/nrclinonc.2012.87","article-title":"Paediatric and adult malignant glioma: close relatives or distant cousins?","volume":"9","author":"Jones C","year":"2012","unstructured":"Jones C, Perryman L, Hargrave D. Paediatric and adult malignant glioma: close relatives or distant cousins?. Nat Rev Clin Oncol. 2012;9(7):400\u2013413.10.1038\/nrclinonc.2012.87"},{"issue":"7384","key":"b27","series-title":"Nature","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1038\/nature10833","article-title":"Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma","volume":"482","author":"Schwartzentruber J","year":"2012","unstructured":"Schwartzentruber J, Korshunov A, Liu XY, Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma. Nature. 2012;482(7384):226\u2013231.10.1038\/nature1083322286061"},{"issue":"18","key":"b28","series-title":"J Clin Oncol","doi-asserted-by":"publisher","first-page":"3061","DOI":"10.1200\/JCO.2009.26.7252","article-title":"Integrated molecular genetic profiling of pediatric high-grade gliomas reveals key differences with the adult disease","volume":"28","author":"Paugh BS","year":"2010","unstructured":"Paugh BS, Qu C, Jones C, Integrated molecular genetic profiling of pediatric high-grade gliomas reveals key differences with the adult disease. J Clin Oncol. 2010;28(18):3061\u20133068.10.1200\/JCO.2009.26.725220479398"},{"issue":"1","key":"b29","series-title":"J Neurooncol","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11060-016-2349-9","article-title":"The role of histone modifications and telomere alterations in the pathogenesis of diffuse gliomas in adults and children","volume":"132","author":"Lee J","year":"2017","unstructured":"Lee J, Solomon DA, Tihan T. The role of histone modifications and telomere alterations in the pathogenesis of diffuse gliomas in adults and children. J Neurooncol. 2017;132(1):1\u201311.10.1007\/s11060-016-2349-928064387"},{"issue":"1","key":"b30","series-title":"Neuro Oncol","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1093\/neuonc\/not144","article-title":"H3F3A K27M mutations in thalamic gliomas from young adult patients","volume":"16","author":"Aihara K","year":"2014","unstructured":"Aihara K, Mukasa A, Gotoh K, H3F3A K27M mutations in thalamic gliomas from young adult patients. Neuro Oncol. 2014;16(1):140\u2013146.2428554710.1093\/neuonc\/not144"},{"issue":"7-8","key":"b31","series-title":"Cancer Genet","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/j.cancergen.2015.04.008","article-title":"Clinicopathology of diffuse intrinsic pontine glioma and its redefined genomic and epigenomic landscape","volume":"208","author":"Panditharatna E","year":"2015","unstructured":"Panditharatna E, Yaeger K, Kilburn LB, Clinicopathology of diffuse intrinsic pontine glioma and its redefined genomic and epigenomic landscape. Cancer Genet. 2015;208(7-8):367\u2013373.10.1016\/j.cancergen.2015.04.00826206682"},{"issue":"10 Pt 1","key":"b32","series-title":"Clin Cancer Res","first-page":"3620","article-title":"ERBB1 is amplified and overexpressed in high-grade diffusely infiltrative pediatric brain stem glioma","volume":"9","author":"Gilbertson RJ","year":"2003","unstructured":"Gilbertson RJ, Hill DA, Hernan R, ERBB1 is amplified and overexpressed in high-grade diffusely infiltrative pediatric brain stem glioma. Clin Cancer Res. 2003;9(10 Pt 1):3620\u20133624.14506149"},{"issue":"5)(suppl","key":"b33","series-title":"J Neurosurg","first-page":"418","article-title":"Rarity of PTEN deletions and EGFR amplification in malignant gliomas of childhood: results from the Children\u2019s Cancer Group 945 cohort","volume":"105","author":"Pollack IF","year":"2006","unstructured":"Pollack IF, Hamilton RL, James CD, Rarity of PTEN deletions and EGFR amplification in malignant gliomas of childhood: results from the Children\u2019s Cancer Group 945 cohort. J Neurosurg. 2006;105(5)(suppl):418\u2013424.17328268"},{"issue":"8","key":"b34","series-title":"J Clin Oncol","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1200\/JCO.2009.25.5463","article-title":"Whole-genome profiling of pediatric diffuse intrinsic pontine gliomas highlights platelet-derived growth factor receptor alpha and poly (ADP-ribose) polymerase as potential therapeutic targets","volume":"28","author":"Zarghooni M","year":"2010","unstructured":"Zarghooni M, Bartels U, Lee E, Whole-genome profiling of pediatric diffuse intrinsic pontine gliomas highlights platelet-derived growth factor receptor alpha and poly (ADP-ribose) polymerase as potential therapeutic targets. J Clin Oncol. 2010;28(8):1337\u20131344.2014258910.1200\/JCO.2009.25.5463"},{"issue":"9","key":"b35","series-title":"Mol Cancer Ther","doi-asserted-by":"publisher","first-page":"2166","DOI":"10.1158\/1535-7163.MCT-15-0558","article-title":"Bevacizumab targeting diffuse intrinsic pontine glioma: results of 89Zr-bevacizumab PET imaging in brain tumor models","volume":"15","author":"Jansen MHA","year":"2016","unstructured":"Jansen MHA, Lagerweij T, Sewing ACP, Bevacizumab targeting diffuse intrinsic pontine glioma: results of 89Zr-bevacizumab PET imaging in brain tumor models. Mol Cancer Ther. 2016;15(9):2166\u20132174.10.1158\/1535-7163.MCT-15-055827325687"},{"issue":"18","key":"b36","series-title":"J Clin Oncol","doi-asserted-by":"publisher","first-page":"3069","DOI":"10.1200\/JCO.2009.26.8789","article-title":"Lack of efficacy of bevacizumab plus irinotecan in children with recurrent malignant glioma and diffuse brainstem glioma: a Pediatric Brain Tumor Consortium study","volume":"28","author":"Gururangan S","year":"2010","unstructured":"Gururangan S, Chi SN, Young Poussaint T, Lack of efficacy of bevacizumab plus irinotecan in children with recurrent malignant glioma and diffuse brainstem glioma: a Pediatric Brain Tumor Consortium study. J Clin Oncol. 2010;28(18):3069\u20133075.10.1200\/JCO.2009.26.878920479404"},{"issue":"1","key":"b37","series-title":"Neuro Oncol","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1215\/S1522851705000529","article-title":"Comparison of linear and volumetric criteria in assessing tumor response in adult high-grade gliomas","volume":"8","author":"Shah GD","year":"2006","unstructured":"Shah GD, Kesari S, Xu R, Comparison of linear and volumetric criteria in assessing tumor response in adult high-grade gliomas. Neuro Oncol. 2006;8(1):38\u201346.10.1215\/S152285170500052916443946"},{"issue":"1","key":"b38","series-title":"Interv Neuroradiol","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1177\/159101991001600109","article-title":"Balloon-assisted superselective intra-arterial cerebral infusion of bevacizumab for malignant brainstem glioma. A technical note","volume":"16","author":"Riina HA","year":"2010","unstructured":"Riina HA, Knopman J, Greenfield JP, Balloon-assisted superselective intra-arterial cerebral infusion of bevacizumab for malignant brainstem glioma. A technical note. Interv Neuroradiol. 2010;16(1):71\u201376.10.1177\/15910199100160010920377982"}],"container-title":["Journal of Neurosurgery: Pediatrics"],"original-title":[],"link":[{"URL":"https:\/\/thejns.org\/view\/journals\/j-neurosurg-pediatr\/28\/4\/article-p371.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/thejns.org\/downloadpdf\/journals\/j-neurosurg-pediatr\/28\/4\/article-p371.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/thejns.org\/downloadpdf\/journals\/j-neurosurg-pediatr\/28\/4\/article-p371.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T01:56:46Z","timestamp":1792807006000},"score":1,"resource":{"primary":{"URL":"https:\/\/thejns.org\/view\/journals\/j-neurosurg-pediatr\/28\/4\/article-p371.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10]]},"references-count":38,"journal-issue":{"issue":"4"},"URL":"https:\/\/doi.org\/10.3171\/2021.3.peds20738","relation":{},"ISSN":["1933-0707","1933-0715"],"issn-type":[{"value":"1933-0707","type":"print"},{"value":"1933-0715","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10]]}}}